Interestingly, epigenetic dysregulation through DNA methylation and miRNA expression modulation could represent a novel mechanism of PI3K‐Akt‐mTOR pathway alterations, which harbours mutations in about 15% of pancreatic NETs and has proven to be a successful target in a wide spectrum of NETs as demonstrated by the mTOR inhibitor Everolimus [44]. This evidence concerns the gene AKT1 and pancreatitis.